Day Zero Diagnostics
Dr. Hooper is Chief of the Infection Control Unit and Associate Chief of the Division of Infectious Diseases at the Massachusetts General Hospital. He is also the former Director of the Antimicrobial Stewardship Program at MGH.
Dr. Hooper’s research has focused on mechanisms of antimicrobial action and resistance with a particular emphasis on fluoroquinolones. His laboratory has received continuous funding from the NIH for the past 30 years, and he is a recipient of an NIH Merit Award. He is author of over 200 peer-reviewed articles on mechanisms and epidemiology of antimicrobial resistance and 76 book chapters and other articles.
Dr. Hooper is a Fellow of the American Academy of Microbiology and the Infectious Diseases Society of America and a Member of the Association of American Physicians. He has served as Chair of the Drug Discovery and Antimicrobial Resistance Study Section of the NIH and Chair of the Scientific Program Committee of the Interscience Conference on Antimicrobial Agents and Chemotherapy of the ASM. He is past President and past Meetings Board Chair of the ASM, has served on the editorial board of Antimicrobial Agents and Chemotherapy, and is Deputy Editor of The Journal of Infectious Diseases.
This person is not in the org chart
This person is not in any offices
Day Zero Diagnostics
The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and the proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale.